

## REMARKS/ARGUMENTS

### Restriction Requirement

The Examiner has required restriction to one of the following inventions:

Group 1, Claim(s) 1-8, as drawn to an isolated nucleic acid having at least 80% identity with the nucleic acid that encodes a polypeptide of SEQ ID NO: 2, a vector comprising the same, a host cell comprising the vector and a process of producing a polypeptide of SEQ ID NO: 2.

Group 2, Claim(s) 1-8, as drawn to an isolated nucleic acid having at least 80% identity with the nucleic acid that encodes a polypeptide of SEQ ID NOS 4,6 ..... 207, 209, a vector comprising a nucleic acid of SEQ ID NOS: 3....206, 208, a host cell comprising the vector and a process of producing a polypeptide of SEQ ID NOS: 4,6 ... .... 207, 209.

Group 3, Claim(s) 9-11, 14-17, in part, drawn to an isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence of the SEQ ID NOS: 2,4, 6....207 and 209, a chimeric molecule fused to a heterologous polypeptide, and a composition.

Group 4, Claim(s) 12-17, as drawn to an antibody which specifically binds to an amino acid sequence of SEQ ID NOS: 2,4,6 .... 207 and 209 and a kit comprising an antibody which specifically binds to an amino acid sequence of SEQ ID NOS: 2, 4, 6.....207 and 209.

Group 5, Claim(s) 14-17, as drawn to a composition of an agonist of a polypeptide of SEQ ID NOS: 2, 4, 6.....207 and 209, and a kit comprising an agonist of a polypeptide of SEQ ID NOS: 2, 4,6 .... 207 and 209.

Group 6, Claim(s) 14-17, as drawn to a composition of an antagonist of a polypeptide of SEQ ID NOS: 2, 4,6 ..... 207 and 209, and a kit comprising an antagonist of a polypeptide of SEQ ID NOS: 2,4,6 .... 207 and 209.

Group 7, Claim(s) 18-19, and 27 as drawn to a method of treating an immune related disorder in a mammal comprising administering a therapeutically effective amount of a polypeptide of an amino acid sequence of SEQ ID NOS: 2,4,6 .... 207 and 209 or an agonist an amino acid sequence of SEQ ID NOS: 2, 4,6 .... 207 and 209.

Group 8, Claim(s) 18-19, as drawn to a method of treating an immune related disorder in a mammal comprising administering a therapeutically effective amount of an antagonist of an amino acid sequence of SEQ ID NOS: 2, 4,6 ... ..207 and 209 or an antibody which binds to an amino acid sequence of SEQ ID NOS: 2,4,6 .....2 07 and 209.

Group 9, Claim(s) 20, drawn to a method of determining the presence of a polypeptide having an amino acid sequence of the SEQ ID NOS: 2, 4,6 ..... 207 and 209 comprising an antibody which binds to a polypeptide of SEQ ID NOS: 2,4,6 ..... 207 and 209.

Group 10, Claim(s) 21 and 28, drawn to a method of diagnosing an immune related disease in a mammal comprising detecting the level of gene expression of a gene that encodes a polypeptide of SEQ ID NOS: 2,4,6 ..... 207 and 209.

Group 11, Claim(s) 22, drawn to a method of diagnosing an immune related disease in a mammal comprising detecting the formation of a complex between the antibody and a polypeptide of SEQ ID NOS: 2,4,6 ..... 207 and 209.

Group 12, Claim(s) 23, drawn to a method of identifying a compound that inhibits the activity of PRO polypeptide of SEQ ID NOS 2, 4,6 ... 207 and 209.

Group 13, Claim(s) 24-25, drawn to a method of identifying a compound that inhibits the expression of a gene encoding a PRO polypeptide of SEQ ID NOS: 2,4,6 ..... 207 and 209.

Group 14, Claim(s) 26, drawn to a method of identifying a compound that mimics the activity of a PRO polypeptide of SEQ ID NOS: 2, 4,6 ..... 207 and 209 comprising contacting cells which respond to said polypeptide with a candidate compound.

The Examiner further asserts that, we are required to choose on SEQ ID NO for the claimed nucleic acid or polypeptide sequence for Groups 2-14.

In addition, a species election is required for Groups 7-8 to elect one species from the immune-related disorders.

Applicants elect Group 3, Claim(s) 9-11, 14-17, in part, drawn to an isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence of the SEQ ID NOS: 2, 4, 6....207 and 209, a chimeric molecule fused to a heterologous polypeptide, and a composition. Applicants further select SEQ ID NO:130 (PRO6492) for the elected claims.

### CONCLUSION

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned agent at the telephone number shown below.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39766-0276 RI).

Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully Submitted,

Date: January 23, 2008  
By:   
Panpan Gao (Reg. No. 43,626)

**HELLER EHRLMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2328609 v1  
(39766.0276)